Several antagonists with excellent activity against CDK4 and CDK6 have been approved for treatment of breast cancer, which restore cell cycle control at the G1/S transition and significantly extend patients' lives [12, 25–28]. This evidence concerns the gene CDK6 and breast carcinoma.